# An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

> **NCT05368818** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 767 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **OTHER:** Secukinumab

## Key facts

- **NCT ID:** NCT05368818
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2021-05-06
- **Final completion:** 2021-05-06
- **Target enrollment:** 767 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368818, "An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05368818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*